Emma Mhic Mhathúna, who is terminally ill with cervical cancer, is to move nearer to Dublin where she is receiving excellent treatment for her illness, the High Court has been told.

Ms Mhic Mhathúna's case was back before the court where her lawyers asked for an extra €650,000 to be paid out of the €7.5m awarded to her and to her children in settlement of her case against the Health Service Executive and a US laboratory.

Ms Mhic Mhathúna was diagnosed with cervical cancer in 2016 but earlier this year she found out that a 2013 smear test, which was incorrectly reported as being normal, was later found to show signs of cancer.

Her senior counsel, Patrick Treacy, told the court that the plan had been for Ms Mhic Mhathúna to buy a house in Ballydavid in Co Kerry where she is currently living.

But he said for various reasons, it had now been decided she would buy a house nearer to Dublin. 

He said her uncle and his wife would be centrally involved in the future care of Ms Mhic Mhathúna's children, who are aged between two and 16.

Her father, who is currently living in the UK, would be spending more time here and it would be better if she was based near to Dublin.  

And he said she was currently receiving excellent care for her cancer in Dublin.  

He said the house it was proposed to buy in Ballydavid had also been found to have structural problems.

Mr Treacy said a property had been located far closer to Dublin with an asking price of €1.25m. He said it was intended to buy this house in the names of Ms Mhic Mhathúna and her five children.

A sum of €500,000 was also due to Ms Mhic Mhathúna in special damages, he said.

Mr Justice Cross said he was sorry that the planned purchase of the property in Co Kerry fell through but he would order the additional money be paid out.

Read more:
Emma Mhic Mhathúna settles case for €7.5m
Emma Mhic Mhathúna says cancer has spread to her brain

The mother-of-five is one of the 209 women affected by the cervical cancer controversy.

They received incorrect smear test results, which were discovered during a clinical audit by the CervicalCheck screening programme.